A Chester medical group has been handed the exclusive license and supply rights to a mouth spray which could treat dry mouth, a symptom common in cancer patients
IS Pharma will launch the lubricating and protective oral spray Aequasya later this year after a deal with privately-owned French pharmaceutical group Laboratoires Carilène.
The spray, which treats xerostomia or dry mouth, has already been successfully marketed in France and the US because of the duration of time over which it reduces the pain and inflammation caused.
Tim Wright, chief executive of IS Pharma said: “Laboratoires Carilène has developed an excellent product in Aequasyal with already proven sales success; we are delighted to become their UK partner.”
Under the terms of the agreement IS Pharma has also acquired the option for exclusive rights to Aequasyal in Germany.
Copyright Press Association 2010